Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Feuring-Buske

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
Der Internist|April 20, 2006
[Stem cell therapy]M Feuring-Buske, W Hiddemann
Blood|June 5, 2001
Hoechst 33342 efflux identifies a subpopulation of cytogenetically normal CD34(+)CD38(-) progenitor cells from patients with acute myeloid leukemiaM Feuring-Buske, D E Hogge
Der Internist|April 1, 2006
[Stem cell therapy. Biology of hematopoietic stem cells]C Buske, H Glimm, M Feuring-Buske
Der Internist|January 15, 2003
[Pathogenesis and biology of leukemias]M Feuring-Buske, W Hiddemann, C Buske
Cell Cycle (Georgetown, Tex.)|November 19, 2005
AML1-ETO needs a partner: new insights into the pathogenesis of t(8;21) leukemiaF Kuchenbauer, M Feuring-Buske, C Buske
Deutsche Medizinische Wochenschrift (1946)|August 5, 1999
[New developments in therapy of non-Hodgkin lymphomas with monoclonal antibodies]C Buske, M Feuring-Buske, M Unterhalt, et al.
European Journal of Cancer (Oxford, England : 1990)|September 24, 1999
Monoclonal antibody therapy for B cell non-Hodgkin's lymphomas: emerging concepts of a tumour-targeted strategyC Buske, M Feuring-Buske, M Unterhalt, et al.
Annals of Hematology|June 2, 2000
Recent advances in antigen-targeted therapy in non-Hodgkin's lymphomaM Feuring-Buske, C Buske, M Unterhalt, et al.
MMW Fortschritte Der Medizin|August 3, 2007
[Nonsymptomatic leukocytosis]D Sauter, K Spiekermann, M Feuring-Buske, et al.
Experimental Hematology|January 9, 2001
Variable cytotoxicity of diphtheria toxin 388-granulocyte-macrophage colony-stimulating factor fusion protein for acute myelogenous leukemia stem cellsM Feuring-Buske, A Frankel, B Gerhard, et al.
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
Der Internist|April 20, 2006
[Stem cell therapy]M Feuring-Buske, W Hiddemann
Blood|June 5, 2001
Hoechst 33342 efflux identifies a subpopulation of cytogenetically normal CD34(+)CD38(-) progenitor cells from patients with acute myeloid leukemiaM Feuring-Buske, D E Hogge
Der Internist|April 1, 2006
[Stem cell therapy. Biology of hematopoietic stem cells]C Buske, H Glimm, M Feuring-Buske
Der Internist|January 15, 2003
[Pathogenesis and biology of leukemias]M Feuring-Buske, W Hiddemann, C Buske
Cell Cycle (Georgetown, Tex.)|November 19, 2005
AML1-ETO needs a partner: new insights into the pathogenesis of t(8;21) leukemiaF Kuchenbauer, M Feuring-Buske, C Buske
Deutsche Medizinische Wochenschrift (1946)|August 5, 1999
[New developments in therapy of non-Hodgkin lymphomas with monoclonal antibodies]C Buske, M Feuring-Buske, M Unterhalt, et al.
European Journal of Cancer (Oxford, England : 1990)|September 24, 1999
Monoclonal antibody therapy for B cell non-Hodgkin's lymphomas: emerging concepts of a tumour-targeted strategyC Buske, M Feuring-Buske, M Unterhalt, et al.
Annals of Hematology|June 2, 2000
Recent advances in antigen-targeted therapy in non-Hodgkin's lymphomaM Feuring-Buske, C Buske, M Unterhalt, et al.
MMW Fortschritte Der Medizin|August 3, 2007
[Nonsymptomatic leukocytosis]D Sauter, K Spiekermann, M Feuring-Buske, et al.
Experimental Hematology|January 9, 2001
Variable cytotoxicity of diphtheria toxin 388-granulocyte-macrophage colony-stimulating factor fusion protein for acute myelogenous leukemia stem cellsM Feuring-Buske, A Frankel, B Gerhard, et al.
Pageof 4